%0 Journal Article
%A Worst, Barbara
%A van Tilburg, Cornelis Martinus
%A Balasubramanian, Gnana Prakash
%A Fiesel, Petra
%A Witt, Ruth
%A Freitag, Angelika
%A Boudalil, Miream
%A Previti, Christopher
%A Wolf, Stephan
%A Schmidt, Sabine
%A Chotewutmontri, Sasithorn
%A Bewerunge-Hudler, Melanie
%A Schick, Matthias
%A Schlesner, Matthias
%A Hutter, Barbara
%A Taylor, Lenka
%A Borst, Tobias
%A Sutter, Christian
%A Bartram, Claus R
%A Milde, Till
%A Pfaff, Elke
%A Kulozik, Andreas E
%A von Stackelberg, Arend
%A Meisel, Roland
%A Borkhardt, Arndt
%A Reinhardt, Dirk
%A Klusmann, Jan-Henning
%A Fleischhack, Gudrun
%A Tippelt, Stephan
%A Dirksen, Uta
%A Jürgens, Heribert
%A Kramm, Christof M
%A von Bueren, Andre O
%A Westermann, Frank
%A Fischer, Matthias
%A Burkhardt, Birgit
%A Wößmann, Wilhelm
%A Nathrath, Michaela
%A Bielack, Stefan S
%A Frühwald, Michael C
%A Fulda, Simone
%A Klingebiel, Thomas
%A Koscielniak, Ewa
%A Schwab, Matthias
%A Tremmel, Roman
%A Driever, Pablo Hernáiz
%A Schulte, Johannes H
%A Brors, Benedikt
%A von Deimling, Andreas
%A Lichter, Peter
%A Eggert, Angelika
%A Capper, David
%A Pfister, Stefan
%A Jones, David
%A Witt, Olaf
%T Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
%J European journal of cancer
%V 65
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2017-06049
%P 91 - 101
%D 2016
%X The Individualized Therapy for Relapsed Malignancies in Childhood (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9). Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses. Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board. Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52. Turnaround time from sample receipt until first report averaged 28 d. Twenty-six patients (50
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27479119
%R 10.1016/j.ejca.2016.06.009
%U https://inrepo02.dkfz.de/record/130973